Affiliation: University of Rochester
- Antithrombotic and thrombolytic therapy for ischemic strokeCurtis Benesch
Department of Neurology, University of Rochester School of Medicine and Dentistry, Box 681, 601 Elmwood Avenue, Rochester, NY 14642, USA
Curr Atheroscler Rep 5:267-75. 2003..Intravenous tissue plasminogen activator is the only approved therapy for patients with acute ischemic stroke. Intra-arterial thrombolysis is emerging as a promising therapy in selected patients...
- Prognosis and decision making in severe strokeRobert G Holloway
Department of Neurology, University of Rochester School of Medicine, Rochester, NY 14642, USA
JAMA 294:725-33. 2005..An increasing number of deaths following severe stroke are due to terminal extubations. Variation in withdrawal-of-care practices suggests the possibility of unnecessary prolongation of suffering or of unwanted deaths...
- Cost-effectiveness of treating resistant hypertension with an implantable carotid body stimulatorKate C Young
Department of Surgery, School of Medicine and Dentistry, University of Rochester, Rochester, NY 14620, USA
J Clin Hypertens (Greenwich) 11:555-63. 2009..Rheos may be cost-effective, with an ICER between $50,000 and $100,000 per QALYs. Cohort characteristics and efficacy are key to the cost-effectiveness of new therapies for resistant hypertension ...
- Hospital resource use following carotid endarterectomy in 2006: analysis of the nationwide inpatient sampleKate C Young
Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
J Stroke Cerebrovasc Dis 19:458-64. 2010..09-2.76). Hospital LOS and costs following CEA increased with increasing patient age. Morbidity after CEA should be discussed with patients in whom revascularization for asymptomatic disease is being considered...
- A cost-effectiveness analysis of carotid artery stenting compared with endarterectomyKate C Young
Department of Surgery, University of Rochester Medical Center, Rochester, New York, USA
J Stroke Cerebrovasc Dis 19:404-9. 2010..With 59% probability, CEA will be the optimal intervention when all of the model assumptions are varied simultaneously...
- Cost-effectiveness of multimodal CT for evaluating acute strokeKate C Young
Department of Neurology, University of Rochester, 601 Elmwood Ave, Box 681, Rochester, NY 14642, USA
Neurology 75:1678-85. 2010..Our goal is to explore the cost-effectiveness of multimodal CT as a diagnostic test...
- Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosisMarc I Chimowitz
Department of Neurology, School of Medicine, Emory University, Atlanta, USA
N Engl J Med 352:1305-16. 2005..Atherosclerotic intracranial arterial stenosis is an important cause of stroke. Warfarin is commonly used in preference to aspirin for this disorder, but these therapies have not been compared in a randomized trial...
- Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosisScott E Kasner
Department of Neurology, University of Pennsylvania Medical Center, Philadelphia, PA, USA
Circulation 113:555-63. 2006..A prespecified aim of WASID was to identify patients at highest risk for stroke in the territory of the stenotic artery who would be the target group for a subsequent trial comparing intracranial stenting with medical therapy...
- Clinical Trial for Stroke with Activated Protein CCurtis Benesch; Fiscal Year: 2008..This should enable us, based on the outcome of the proposed pilot study, to design and conduct a larger Phase II safety and efficacy trial of APC in patients with acute ischemic stroke. [unreadable] [unreadable] [unreadable]..